P^(73)、CD59、MMP-19在上皮性卵巢癌及交界性肿瘤中的表达

The Expression of P^(73)、CD59、MMP-19 in Epithelial Ovarian Cancer and Borderlane Tumors

目的:研究P73、CD59、MMP-19在上皮性卵巢癌及交界性肿瘤中的表达,探讨上述标记物在卵巢上皮性肿瘤发病机制上的作用。方法:取87例卵巢癌、27例交界性肿瘤,分别制成40点的12块组织芯片,用免疫组织化学的方法检测组织芯片中P73、CD59、MMP-19的表达情况,并收集卵巢癌病例的临床病理资料分析其与这些蛋白表达的关系。结果:卵巢癌与交界性肿瘤组中P73的表达有显著性差异(Z=-3.203,P=0.001),CD59、MMP-19的表达无差异;卵巢癌组P73、CD59、MMP-19的阳性表达率分别为46.0%(40/87)、83.9%(73/87)、83.9%(73/87);交界性肿瘤组P73、CD59、MMP-19的阳性表达率分别为70.4%(19/27)、81.5%(22/27)、85.2%(23/27),两组中不同组织类型肿瘤在P73的表达率上均存在明显差异(卵巢癌组:χ2=19.144,P=0.001;交界性肿瘤组χ2=7.849,P=0.013)。结论:上皮性卵巢癌中P73的表达明显低于交界性肿瘤,其表达情况与组织类型有关,提示P73作为肿瘤抑制基因,它的丢失可能与卵巢癌的发病密切相关。

Objective ：To study the expression of p73 ,CD59 ,MMP - 19 in the epithelial ovarian carcinoma and epithelial borderline tumors, and to investigate their use in pathogenesis of ovarian cancer and epithelial borderline tumors. Methods：87 cases of ovarian carcinomas and 27 cases of ovarian borderline tumors in People＇s Hospital, Peking University were reviewed retrospectively. Immunohistochemical study for p^73 、 CD59, MMP - 19 was performed in all these cases. Results： There were significant difference in expression for p^73 between borderline tumors and carcinomas （ Z = - 3. 203,P = 0. 001 ）, But There were no difference in expression for CD59, MMP - 19; Overexpression of p73 ,CD59 ,MMP - 19 was observed in 46. 0% （40/87） ,83.9% （73/87） ,83.9% （73/87） of ovarian carcinomas, Overexpression of p73, CD59 ,MMP - 19 was observed in 70. 4% （19/27） ,81.5% （22/27） ,85.2% （23/27） of ovarian borderline tumors. There were significant difference in expression for p73 among different histological types of borderline tumors and carcinomas（ ovarian carcinomas ：X^2 = 19. 144 ,P = 0. 001 ; ovarian borderline tumors X^2 = 7. 849, P = 0. 013 ）. Conclusions ： Epithelial ovarian borderline tumors are distinct from ovarian cancer in expression of p73, The expression of p73 in ovarian carcinoma was correlated with the histological types, The p^73 may be an important molecular change and play a certain role in malignant progression of ovarian tumor from borderline tumors to carcinoma.